In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Candel Therapeutics, with a price target of $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding Candel Therapeutics’ CAN-2409. The recent Phase 3 analyses for CAN-2409 in intermediate-to-high-risk localized prostate cancer have shown promising results, particularly with a 30% reduction in disease recurrence. This efficacy, along with a favorable safety profile characterized by mild flu-like symptoms, positions CAN-2409 as a strong candidate for integration into existing treatment regimens, either as an adjunct or replacement for androgen deprivation therapy (ADT).
Furthermore, the feedback from key opinion leaders (KOLs) underscores the therapy’s potential for widespread adoption in community urology practices, where the emphasis is on recurrence reduction and quality of life rather than overall survival data. The consensus among KOLs is that disease-free survival (DFS) is a clinically meaningful endpoint, supporting the case for CAN-2409’s approval. Additionally, the potential for CAN-2409 to expand into other solid tumors like PDAC and NSCLC further strengthens its appeal, making it a compelling investment opportunity.
According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 21.8% and a 60.00% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Candel Therapeutics, and Protara Therapeutics.